文献速递胸部肿瘤

阿贝西利用于p16ink4A缺陷型间皮瘤患者(MiST2):单臂、开放标签、2期试验

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2022-02-11

MiST2是一项在两家英国中心开展的单臂、开放标签、2期试验,评估阿贝西利200 mg每日两次口服用于既往接受过铂类化疗后进展的p16ink4A阴性间皮瘤患者。26例可评估患者12周疾病控制率为54%(95% CI 36-71),达到主要终点;≥3级治疗相关不良事件发生在12%的患者,1例(4%)因不良事件死亡。作者认为结果 promising,需在随机研究中进一步评估。

要点

  • p16ink4A阴性间皮瘤患者接受阿贝西利200 mg每日两次口服,12周疾病控制率为54%(95% CI 36-71)。
  • ≥3级治疗相关不良事件发生在3/26(12%)患者,1例(4%)因中性粒细胞减少性脓毒症死亡。
  • 作者认为阿贝西利在该人群中显示有前景的临床活性,需在随机研究中进一步评估。

核心结论

  • 本研究达到主要终点,显示阿贝西利在既往化疗后的p16ink4A阴性间皮瘤患者中具有有前景的临床活性,作者认为需在随机研究中作为靶向分层治疗进一步研究。

研究设计与样本

  • MiST2为在两家英国中心开展的单臂、开放标签、2期临床试验,纳入组织学确诊的胸膜或腹膜间皮瘤、至少一线铂类化疗后影像学进展、p16ink4A免疫组化阴性、ECOG评分0-1的18岁以上患者。
  • 患者接受阿贝西利200 mg每日两次口服,28天为一周期,给药24周;主要终点为12周疾病控制率,若至少11例患者达到疾病控制则可拒绝无效假设。
  • 2019年9月31日至2020年3月2日期间27例合格患者同意分子筛查,中位随访18.4周(IQR 6.7-23.9),1例在治疗前因严重不良事件排除,26例接受至少一剂阿贝西利并纳入疗效和安全性分析。

主要发现

  • 26例接受治疗的患者均为p16ink4A缺陷,12周疾病控制率为14/26(54%,95% CI 36-71)。
  • 任何原因的≥3级治疗相关不良事件发生在8/26(27%)患者,包括腹泻、呼吸困难、血小板减少、呕吐、尿路感染、丙氨酸氨基转移酶升高、腹水、胸部感染或疑似胸部感染、中性粒细胞减少性脓毒症、脱发、左小腿血栓、跌倒(颈部和锁骨骨折)、咯血、下呼吸道感染和肺栓塞。
  • ≥3级治疗相关不良事件发生在3/26(12%)患者,包括腹泻、血小板减少、呕吐、丙氨酸氨基转移酶升高和肺栓塞。
  • 严重不良事件发生在6/26(23%)患者,导致1/26(4%)患者终止治疗;1/26(4%)患者因不良事件(中性粒细胞减少性脓毒症)死亡,1例患者发生与阿贝西利相关的严重不良事件(腹泻)。

临床怎么用

  • 作者认为阿贝西利在既往化疗后的p16ink4A阴性间皮瘤患者中显示有前景的临床活性,需在随机研究中作为靶向分层治疗进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetically stratified therapy for malignant mesothelioma is unavailable. Mesotheliomas frequently harbour loss of the chromosome 9p21.3 locus (CDKN2A-MTAP), which is associated with shorter overall survival due to loss of the tumour suppressor p16ink4A, an endogenous suppressor of cyclin-dependent kinase (CDK)4 and CDK6. Genetic restoration of p16ink4A suppresses mesothelioma in preclinical models, underpinning the rationale for targeting CDK4 and CDK6 in p16ink4A-negative mesothelioma. We developed a multicentre, stratified, phase 2 trial to test this hypothesis. METHODS: The MiST2 study was a single-arm, open-label, phase 2 clinical trial done two UK centres. Patients older than 18 years with any histologically confirmed subtype of mesothelioma (pleural or peritoneal) with radiological progression after at least one course of platinum-based chemotherapy were molecularly screened by immunohistochemistry for p16ink4A. Patients with p16ink4A-negative mesothelioma were eligible for inclusion in the study. Patients were required to have measurable disease by modified Response Evaluation Criteria in Solid Tumours version 1.1 for malignant mesothelioma, a predicted life expectancy of at least 12 weeks, and an Eastern Cooperative Oncology Group performance status score of 0-1. Patients received oral abemaciclib 200 mg twice daily, administered in 28-day cycles for 24 weeks. The primary endpoint was the disease control rate (patients with complete responses, partial responses, or stable disease) at 12 weeks. The null hypothesis could be rejected if at least 11 patients had disease control. The efficacy and safety populations were defined as all patients who received at least one dose of the study drug. The study is registered with ClinicalTrials.gov, NCT03654833, and is ongoing (but MiST2 is now closed). FINDINGS: Between Sept 31, 2019, and March 2, 2020, 27 eligible patients consented to molecular screening. The median follow-up was 18·4 weeks (IQR 6·7-23·9). One patient was excluded before treatment because of a serious adverse event before study drug allocation. 26 (100%) of 26 treated patients were p16ink4A deficient and received at least one dose of abemaciclib. Disease control at 12 weeks was reported in 14 (54%) of 26 patients (95% CI 36-71). Grade 3 or worse treatment-related adverse events (of any cause) occurred in eight (27%) of 26 patients (diarrhoea, dyspnoea, thrombocytopenia, vomiting, urinary tract infection, increased alanine aminotransferase, ascites, chest infection or suspected chest infection, neutropenic sepsis, alopecia, blood clot left calf, fall [broken neck and collar bone], haemoptysis, lower respiratory tract infection, and pulmonary embolism). Grade 3 or worse treatment-related adverse events occurred in three (12%) of 26 patients (diarrhoea, thrombocytopenia, vomiting, increased alanine aminotransferase, and pulmonary embolism). Serious adverse events occurred in six (23%) of 26 patients, leading to treatment discontinuation in one (4%) patient (diarrhoea, urinary tract infection, chest infection, neutropenic sepsis, fall [broken neck and collar bone], haemoptysis, lower respiratory tract infection, and pulmonary embolism). One patient had a serious adverse event related to abemaciclib (diarrhoea). One (4%) of 26 patients died from an adverse event (neutropenic sepsis). INTERPRETATION: This study met its primary endpoint, showing promising clinical activity of abemaciclib in patients with p16ink4A-negative mesothelioma who were previously treated with chemotherapy, and warrants its further investigation in a randomised study as a targeted stratified therapy. FUNDING: University of Leicester, Asthma UK and British Lung Foundation Partnership, and the Victor Dahdaleh Foundation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fennell DA, King A, Mohammed S, et al. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2022. PMID: 35157829. doi:10.1016/S1470-2045(22)00062-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。